Information message

In order to see all the search results and access content, you must log in. Please use the Log-in button at the top of the page.

Displaying 313 - 324 of 433
Cirrhosis & Complications
ILC 2021 Takeaways – Cirrhosis and complications

ILC 2021 Takeaways – Cirrhosis and complications

Takeaways
View
Liver Tumours
Digital Liver Cancer Summit 2021 Takeaways

Digital Liver Cancer Summit 2021 Takeaways

Takeaways
View
Basic Science
ILC 2021 Takeaways – Basic Science

ILC 2021 Takeaways – Basic Science

Takeaways
View

Nurses & AHPs On-demand Webinar: Management of NAFLD – Integration of different perspectives

Description

This on-demand webinar focuses on highlighting barriers to living with NAFLD and looks at options for addressing them, through interactive debates and expert talks on current evidence and management strategies, including lifestyle interventions.  Learn about the burning topic of NAFLD from a range of perspectives: patient representative, doctor, liver nurse, dietician, and physiotherapist, and take part in small group discussions.  

Target Audience  

This on-demand webinar is intended for nurses and AHPs, but all members of the liver community are welcome.  

 Learning Objectives  

  • Gaining an understanding of the pathophysiology of NAFLD   
  • Reviewing methods for treating NAFLD, the evidence for these methods, and their clinical usefulness 
  • Reviewing the effectiveness of exercise, nutrition, and lifestyle adjustments in the management of NAFLD and the barriers to implementing strategies 
  • Considering the implications of living with NAFLD and its impact on management and care  

 

Time Title
00:00-05:14

Welcome

Dr Patrizia Künzler-Heule, chair of EASL Nurses’ & AHP taskforce, University of Basel, Switzerland

05:14-12:55

Living with NAFLD. What do HCP’s need to know

Mr. Christian Price, patient representative, Birmingham, United Kingdom

12:55-19:40

Q&A

19:40-38:58

NAFLD in a nutshell

Prof. Elisabetta Bugianesi, physician, gastroenterologist, Torino University, Italy

38:58-42:00

Q&A

42:00-57:45

Can exercise make an impact?

Dr Kate Hallsworth, physiotherapist Newcastle biomedical research centre, United Kingdom

57:45-01:03:15

Q&A

01:03:15-01:14:20

The scope of nutritional management in NAFLD

Ms. Tayla Robertson, dietitian, Princess Alexandra Hospital, Brisbane, Australia

01:14:20-01:19:34

Q&A

01:19:34-01:27:35

The impact of treatment on my life

Mr. Christian Price, patient representative, Birmingham, United Kingdom

01:27:35-01:30:12

Summary of webinar and close

Ms. Jennifer Towey, member of EASL Nurses’ & AHP taskforce, Birmingham, United Kingdom

 

 

Speakers

 
Christian Price My name is Christian Price, a former history teacher before I fell ill with NAFLD. I had my transplant in February 2018 followed by a sleeve gastrectomy in 2020 to relieve pressure on my new liver. I currently work as a bookkeeper but am now hoping to return to teaching in the near future. I am a member of the Queen Elizabeth hospital patient participation group for liver and hi research and am helping on the exakt project with Dr Matt Armstrong as a patient representative.
Elisabetta Bugianesi Dr Bugianesi MD, PhD, is currently Professor of Gastroenterology and Scientific Director of the Dept of Medical Sciences at the University of Turin in Italy. Dr Bugianesi received her MD and her Internal Medicine Residency at the University of Bologna. Her post-graduate training included a PhD fellowship at Case Western Reserve University, Cleveland, USA, from 1995 to 1998 where she became expert in the use of stable isotopes to study in vivo metabolism. Dr Bugianesi is an international acknowledged expert on Non-Alcoholic Fatty Liver Disease (NAFLD) with over 15-years experience. She contributed in the field with work describing the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage, the natural history of the disease (including the first demonstration of HCC as a complication of NASH), the development of non-invasive markers of fibrosis, and the involvement in several trials for the treatment of NAFLD/NASH. Her contribution to science is testified by over 200 publications, an H Index = 66, N. Citations = 20730 (Scopus).
Kate Hallsworth Dr Kate Hallsworth is an NIHR Clinical Lecturer and a Senior Research Physiotherapist within the Liver Unit at Newcastle upon Tyne Hospitals NHS Foundation Trust (NuTH). She has published world-leading research in the field of lifestyle management for patients with non-alcoholic fatty liver disease (NAFLD). More recently, her research has looked at why lifestyle interventions are not being optimised in clinical practice and what tools are necessary to aid healthcare professionals to support patients to make lifestyle changes. She led the development of an evidence-based NAFLD-specific digital intervention (VITALISE- interVention to promote lIfesTyle change in non-Alcoholic fatty LIver diseaSE) which was co-designed with patients and will be trialled within the NHS in the coming months.

 

Log in to post comments

EASL–Lancet Liver Commission: Protecting the next generation of Europeans against liver disease complications and premature mortality

Description

This official launch marks the publication of the report of the EASL–Lancet Liver Commission:  Protecting the next generation of Europeans against liver disease complications and premature mortality. This prestigious event is a culmination of many years of collaboration together, with a new momentum toward its solid implementation. The discussion will engage commissioners (contributors to the report), other high-level actors and experts from the European institutions, and patient representatives. Key topics of the report will be discussed, as well as how the European Union policy and funding initiatives can support both the recommendations and application of good practices throughout the EU.

The goal of saving the lives of almost 300,000 people per year across Europe is what is driving this initiative. Policy actions for marketing, pricing, and taxation of alcohol and unhealthy foods are of paramount importance with an ability to reduce premature morbidity and save these hundreds of thousands of lives per year across the region.

Target audience

We warmly invite a broad range of stakeholders including primary care physiciansnursespatientspeers, and members of relevant communities, along with medical specialists trained in obesity, diabetesliver diseaseoncologycardiovascular diseasepublic healthaddictionsinfectious diseasescivil society organisations, representatives from patient organisationspolicymakersmedical associations, and other actors involved in those topics in Europe and beyond.

Time Title
00:00-02:26

Opening remarks

Patrizia Burra (Italy) and Thomas Berg, EASL Secretary-General (Germany)

02:26-09:26

Introductory remarks

Richard Horton, Editor-in-Chief, The Lancet (United Kingdom)

09:26-15:56

Keynote statement on EU health policy

Ursula von der Leyen, President of the European Commission (Belgium)

15:56-25:00

Overview of the EASL-Lancet Liver Commission

Michael Manns, EASL–Lancet Commission Co-chair (Germany)

25:00-32:50

The burden of liver disease in Europe

Nick Sheron (United Kingdom)

32:50-39:44

Children and the power of digital marketing

Shira Zelber-Sagi (Israel)

39:44-46:20

Stigma as a barrier in pathways of liver care

Patrizia Carrieri (France)

46:20-53:53

Primary care hepatology

Rachel Pryke (United Kingdom)

53:53-01:00:27

A paradigm shift in hepatology

Pere Ginès (Spain)

01:00:27-01:27:12

Panel discussion: How to move from recommendations to action?

Moderators:
Jeffrey Lazarus, EASL-Lancet Commissioner (Spain) &
Maria Buti, EASL EU Policy Councillor (Spain)

Participants:
Shlomo Vinker, WONCA (Israel)
Michele Cecchini, OECD (France)
Rachel Halford, WHA (United Kingdom)

01:27:12-01:39:22

Q&A from audience

01:39:22-01:44:57

Future opportunities of a Lancet Commission

Sabine Kleinert, The Lancet (United Kingdom)

01:44:57-01:48:09

Closing remarks

Tom Hemming Karlsen, EASL–Lancet Commission Co-chair (Norway)

Speakers

Ursula von der Leyen

Thomas Berg

Patrizia Burra

Maria Buti

Patrizia Carrieri

Ursula von der Leyen
President of the European Commission

Prof. Thomas Berg
EASL Secretary General

Prof. Patrizia Burra
EASL-Lancet Commission co-chair
Prof. Maria Buti
EASL EU Policy Councillor
Prof. Patrizia Carrieri
EASL-Lancet Commissioner

Michele Cecchini

Pere Gines

Rachel Halford

Richard Horton

George Kalamitsis

Dr Michele Cecchini
OECD

Prof. Pere Gines
EASL-Lancet Commissioner

Rachel Halford
World Hepatitis Alliance European Board Member
Prof. Richard Horton
The Lancet - Editor-in-Chief
George Kalamitsis
Liver Patient International

Tom H. Karlsen

 Sabine Kleinert

Jeffrey Lazarus

Michael Manns

Nick Sheron

Prof. Tom H. Karlsen
EASL-Lancet Commission co-chair

Sabine Kleinert
The Lancet, Senior Executive Editor

Prof. Jeffrey Lazarus
EASL-Lancet Commissioner
Prof. Michael Manns
EASL-Lancet Commission co-chair
Prof. Nick Sheron
EASL Policy and Public Health Committee Member & EASL-Lancet Commissioner

Rachel Pryke

Shlomo Vinker

Shira Zelber-Sagi

Dr Rachel Pryke
EASL-Lancet Commissioner

Prof. Shlomo Vinker
World Organisation of Family Doctors (WONCA) 

Prof. Jeffrey Lazarus
EASL-Lancet Commissioner
Log in to post comments
General Hepatology
ILC 2021 Takeaways – Public health

ILC 2021 Takeaways – Public health

Takeaways
View
COVID-19 and the liver
Ask EASL: podcast on COVID-19 vaccination in patients with liver disease

Ask EASL: podcast on COVID-19 vaccination in patients with liver disease

Podcasts
View
Liver Tumours
Ask EASL: podcast on Liver Cancer

Ask EASL: podcast on Liver Cancer

Podcasts
View
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Cyst Infection

ERN Rare-Liver on-demand Webinar: Cyst Infection

On-demand Webinars
View
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Neuromonitoring in Pediatric Acute Liver Failure (PALF) – a controversy

ERN Rare-Liver on-demand Webinar: Neuromonitoring in Pediatric Acute Liver Failure (PALF) – a controversy

On-demand Webinars
View
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: PBC Therapy

ERN Rare-Liver on-demand Webinar: PBC Therapy

On-demand Webinars
View
Rare Liver Diseases
ERN Rare-Liver on-demand Webinar: Update on Alpha-1 Antitrypsin Deficiency in adult and paediatric care

ERN Rare-Liver on-demand Webinar: Update on Alpha-1 Antitrypsin Deficiency in adult and paediatric care

On-demand Webinars
View